HC Wainwright Reiterates “Buy” Rating for Actinium Pharmaceuticals (NYSE:ATNM)

Actinium Pharmaceuticals (NYSE:ATNM)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $4.00 target price on the stock. HC Wainwright’s target price would indicate a potential upside of 247.83% from the stock’s current price.

ATNM has been the topic of a number of other research reports. StockNews.com lowered shares of Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, November 11th. Stephens reiterated an “overweight” rating and set a $5.00 price target on shares of Actinium Pharmaceuticals in a report on Tuesday, November 19th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.40.

Actinium Pharmaceuticals Stock Performance

Shares of NYSE:ATNM opened at $1.15 on Tuesday. The firm has a market cap of $35.88 million, a PE ratio of -0.83 and a beta of 0.10. The firm’s fifty day moving average is $1.21 and its 200-day moving average is $1.49. Actinium Pharmaceuticals has a 52 week low of $1.03 and a 52 week high of $10.24.

Hedge Funds Weigh In On Actinium Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. Vontobel Holding Ltd. bought a new stake in Actinium Pharmaceuticals in the fourth quarter valued at $32,000. Sei Investments Co. bought a new stake in Actinium Pharmaceuticals in the fourth quarter valued at $62,000. Barclays PLC increased its stake in Actinium Pharmaceuticals by 323.0% in the third quarter. Barclays PLC now owns 42,935 shares of the company’s stock valued at $81,000 after purchasing an additional 32,784 shares in the last quarter. Bank of America Corp DE increased its stake in Actinium Pharmaceuticals by 76.6% in the fourth quarter. Bank of America Corp DE now owns 78,767 shares of the company’s stock valued at $99,000 after purchasing an additional 34,176 shares in the last quarter. Finally, Wellington Management Group LLP bought a new stake in Actinium Pharmaceuticals in the third quarter valued at $112,000. Institutional investors and hedge funds own 27.50% of the company’s stock.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).